Below are the most recent publications written about "Mitogen-Activated Protein Kinases" by people in Profiles.
-
Wilson HP, Aplin AE. Site matters in metastatic melanoma. Trends Cancer. 2023 08; 9(8):603-605.
-
Milman T, Eiger-Moscovich M, Henry RK, Ida CM, Ruben M, Shields CL, Lally SE, Penne RB, Stefanyszyn MA, Bilyk JR, Rapuano CJ, Rabinowitz M, Eagle RC. Cyclin D1 Expression and Molecular Genetic Findings in Periocular Histiocytoses and Neoplasms of Macrophage-Dendritic Cell Lineage. Am J Ophthalmol. 2022 10; 242:36-51.
-
Brose MS, Pryma DA, Newbold KL. Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. J Clin Oncol. 2022 06 10; 40(17):1847-1849.
-
Patel P, Naik UP. Platelet MAPKs-a 20+?year history: What do we really know? J Thromb Haemost. 2020 09; 18(9):2087-2102.
-
Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B, Waters I, Rosen DM, Dennison L, Hunter N, Donaldson J, Christenson ES, Konstantopoulos K, Hurley PJ, Croessmann S, Park BH. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat. 2020 Feb; 179(3):631-642.
-
Xu SQ, Buraschi S, Tanimoto R, Stefanello M, Belfiore A, Iozzo RV, Morrione A. Analysis of Progranulin-Mediated Akt and MAPK Activation. Methods Mol Biol. 2018; 1806:121-130.
-
Neill T, Buraschi S, Goyal A, Sharpe C, Natkanski E, Schaefer L, Morrione A, Iozzo RV. EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol. 2016 Dec 05; 215(5):687-703.
-
Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS One. 2015; 10(11):e0142704.
-
Xu SQ, Buraschi S, Morcavallo A, Genua M, Shirao T, Peiper SC, Gomella LG, Birbe R, Belfiore A, Iozzo RV, Morrione A. A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget. 2015 May 10; 6(13):10825-39.
-
Gripp KW, Sol-Church K, Smpokou P, Graham GE, Stevenson DA, Hanson H, Viskochil DH, Baker LC, Russo B, Gardner N, Stabley DL, Kolbe V, Rosenberger G. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences. Am J Med Genet A. 2015 Sep; 167A(9):2085-97.